Records containing: Melanoma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2025-11-10Prophylactic Lymphovenous Bypass Procedure Following Axillary Lymphadenectomy: A Prospective Observational Study
-
CLINICAL_TRIALS study record update · 2025-11-10Testing of an Educational Tool for Patients With Melanoma and Concomitant Autoimmune Disease Who Are Candidates for Adjuvant Therapy With Immune Checkpoint Inhibitors: Acceptability and Usability With Patients and Providers
-
CLINICAL_TRIALS study record update · 2025-11-06A Phase Ib/II Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab in Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2025-11-06Adjuvant Nivolumab or Ipilimumab + Nivolumab Determined By Pathological Response To A Single Dose Of Neoadjvuant Nivolumab
-
CLINICAL_TRIALS study record update · 2025-11-04A Phase III Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy in Patients With Metastatic Cancer
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2025-10-29A Phase I/II, Open Label Study of Ad-RTS-hIL-12, an Adenovirus Vector Engineered to Express hIL-12, in Combination With an Oral Activator Ligand, in Subjects With Unresectable Stage III or IV Melanoma
-
CLINICAL_TRIALS study record update · 2025-10-29A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients With PALB2 Mutations
-
CLINICAL_TRIALS study record update · 2025-10-28SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
-
CLINICAL_TRIALS study record update · 2025-10-28A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02D
-
CLINICAL_TRIALS study record update · 2025-10-27A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02C
-
CLINICAL_TRIALS study record update · 2025-10-24A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
-
CLINICAL_TRIALS study record update · 2025-10-24An Open-Label, Multicenter, Phase 1b/2 Study of E7386 in Combination With Pembrolizumab in Previously Treated Subjects With Selected Solid Tumors
-
CLINICAL_TRIALS study record update · 2025-10-24The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)
-
CLINICAL_TRIALS study record update · 2025-10-22A Phase 1b/2a, Open Label Study to Evaluate Anti-tumor Efficacy and Safety of rhIL-7-hyFc (NT-I7) in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Anti-PD-1/PD-L1 naïve or Relapsed/Refractory High-risk Skin Cancers
-
CLINICAL_TRIALS study record update · 2025-10-22A Dose Escalation Study of HFB301001 (OX40 Agonist Antibody) in Adult Patients With Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2025-10-14Young Adult Survivors United Cancer Research Registry
-
CLINICAL_TRIALS study record update · 2025-10-09RAdiation comBined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) Study: A Phase I/II Study of AMG757 / Tarlatamab and Concurrent Radiation Therapy in Tumors With High Prevalence of DLL3
-
CLINICAL_TRIALS study record update · 2025-10-09Integrative Medicine for Patient-reported Outcomes, Values, and Experience (IMPROVE)
-
CLINICAL_TRIALS study record update · 2025-10-08A Phase 1/2a, Open-Label, Dose Escalation and Expansion Study of the Safety and Tolerability of T3011 Administered Via Intratumoral Injection as a Single Agent and in Combination With Intravenous Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
-
CLINICAL_TRIALS study record update · 2025-10-06Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2025-10-03A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
-
CLINICAL_TRIALS study record update · 2025-10-02ClinicalTrials.gov study NCT00722228
-
CLINICAL_TRIALS study record update · 2025-10-02A Phase 2, Subprotocol of DAY101 Monotherapy for Patients With Recurrent, Progressive, or Refractory Solid Tumors With MAPK Pathway Aberrations
-
CLINICAL_TRIALS study record update · 2025-09-26A Phase 1b, Randomized, Open-Label Trial to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB097 in Combination With Pembrolizumab in Melanoma Patients With Primary Resistance to an AntiPD1Containing Immunotherapy
-
CLINICAL_TRIALS study record update · 2025-09-26Safety and Efficacy of NG2 and DLL3 CAR-T Therapy Targeting Melanoma